CD232抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD232 mouse mAb (green) and negative control (red).    

  
  

CD232. also known as VSTM1 (V-set and transmembrane domain-containing protein 1), is a cell surface glycoprotein belonging to the immunoglobulin superfamily. Identified as part of immune receptor signaling pathways, it is expressed on subsets of immune cells, including T cells and natural killer (NK) cells. CD232 has garnered interest for its potential role in modulating immune responses, though its exact biological function remains under investigation. Early studies suggest it may act as a co-stimulatory or co-inhibitory checkpoint molecule, influencing T-cell activation and cytokine production.

Antibodies targeting CD232 are primarily used as research tools to explore its expression patterns, ligand interactions, and mechanistic contributions to immune regulation. Some preclinical studies indicate that anti-CD232 antibodies could enhance or suppress immune activity depending on context, making it a candidate for immunotherapy development, particularly in cancer or autoimmune diseases. However, clinical relevance remains speculative, with limited data on its therapeutic targeting.

Current research focuses on characterizing CD232's structure, binding partners (e.g., putative ligands like VSIR), and signaling cascades. Its dual Ig-like domains and transmembrane region suggest involvement in cell-cell communication. While still in exploratory stages, CD232 antibodies hold promise for advancing understanding of immune modulation and may inspire novel therapeutic strategies as mechanistic insights evolve.